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a b s t r a c t
Statins are used in primary and secondary prevention of cardiovascular episodes. Most of
recent studies regard ischemic stroke. There are more emerging results of studies suggesting
usefulness of these drugs in the other types of stroke e.g. intracerebral hemorrhage (ICH) and
subarachnoid hemorrhage (SAH). Searching for new methods of treatment is important,
because both ICH and SAH lead to poor prognosis and severe psychomotor disability.
The unquestionable role of inﬂammatory factors in the pathogenesis of these disorders
justiﬁes considering statin treatment. Previous results are contradictory, thus in present
study we review results of studies and try to explain the potential pathomechanism of statin
use in hemorrhagic strokes.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Statins are used in primary and secondary prevention of
cardiovascular episodes. Among neurological disorders they
play a key role in ischemic stroke, but there are reports of
possible beneﬁcial effect of statins in dementia and multiple
sclerosis [1–3].
Most of recent studies regard ischemic stroke. There are
more emerging results of studies suggesting usefulness of
this drugs in other types of stroke e.g. intracerebral hemor-
rhage (ICH) and subarachnoid hemorrhage (SAH). Searching
for new methods of treatment is important, because both ICH
and SAH lead to poor prognosis and severe psychomotor
disability.* Corresponding author at: Department of Neurology, Pomeranian Me
Poland. Tel.: +48 914253251; fax: +48 914253260.
E-mail address: dkotlega@poczta.onet.pl (D. Kotlęga).
http://dx.doi.org/10.1016/j.pjnns.2015.07.007
0028-3843/# 2015 Polish Neurological Society. Published by Elsevier SIn a present study we review results of studies and try to
explain the potential pathomechanism of statin use in
hemorrhagic strokes.
2. Intracerebral hemorrhage
Intracerebral hemorrhage constitutes about 10% of strokes,
leads to severe neurological deﬁcit and mortality remains as
high as 30–50% [4]. In everyday practice there is such a
common notion that statins increase the ICH risk, which was
justiﬁed by the results of some studies [5,6]. It is likely that
such an opinion was unearthed by the results that showed
connection between higher risk of ICH and low cholesterol
level, but not between statins. These results were included indical University, Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin,
p. z o.o. All rights reserved.
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meta-analysis published in 2011 it was unequivocally pre-
sented that statins do not increase the ICH risk [8]. Similar
conclusions were enclosed in the later meta-analysis in 2012
[9]. Moreover, post-ICH statin use is not associated with an
increased risk of ICH recurrence [10].
Unfavorable effects of ICH are connected with initial
mechanical injury produced by the hematoma and further
damage that is believed to occur after the bleeding stops and
called as the perihematomal edema (PE). Hematoma enlarge-
ment was seen for up to 2 days and almost always occurs
within the ﬁrst few hours. Clinical deterioration in subacute
period is provoked by the progression of PE, increase of
intracranial pressure and the risk of herniation. The late
edema progression occurs in the second and third week after
ICH. PE is responsible for about 75% of mass effect [11].
Signiﬁcant midline shift (>3 mm) was reported in 62% of
patients [12].
The formation of edema after ICH follows three distinct
temporal phases: in the ﬁrst hours after ICH, retraction of the
clot begins. As the coagulation cascade becomes activated over
the following 24–48 h, thrombin becomes activated and
promotes edema formation and further disruption of the
integrity of the blood–brain barrier (BBB). The third phase of
edema formation starts when red blood cells in the hematoma
begin to lyse, and hemoglobin with its degradation products
are deposited into the brain parenchyma, thus initiating a
potent inﬂammatory reaction. One presumed function of
hemoglobin degradation products is the generation of reactive
oxygen (ROS) and nitrogen species that would lead to lipid
peroxidation, carboxylation, and tyrosine nitrosylation of
proteins as well as eventual uncoupling of mitochondria.
An additional contributor to neuronal death is the
increased presence of cytokines. Elevated levels of interleu-
kin-6 (Il-6) and Il-10 have been associated with ICH and edema
formation. Components of the complement (C) system have
also been found in the perihematomal area. The presence of
C3d and C9 have been documented in the parenchyma [12].
Mechanisms that trigger pathophysiological changes in
and around the hematoma are linked to the role of thrombin
and iron, released upon red blood cell (RBC) lysis, as 2 major
factors causing brain injury after ICH. Thrombin causes brain
damage at high concentrations and induces neuroprotection
at low concentrations. Thrombin-induced brain injury may be
mediated by the complement cascade. Thrombin activates
matrix metalloproteinase-2 (MMP-2) in endothelial cells and
tumor necrosis factor-a (TNF-a), which is one of the major
proinﬂammatory cytokines. Matrix metalloproteinases are
members of a family of zinc-dependent proteases that can
degrade extracellular matrix and cause blood–brain barrier
disruption [13]. Among 23 types of MMP's several of them were
proved to play a role in the pathogenesis of ICH (MMP-2, 3, 9,
12). Increased level of MMP-3 is associated with mortality, both
MMP-9 and 3 are related to residual cavity volume [14].
Increased level of TNF-a, Il-6 and MMP-9 in the ﬁrst day after
ICH is associated with the size of PE and subsequent
enlargement of the hematoma [15].
Development of inﬂammatory process is connected with
microglia activation and presence of leukocytes and macro-
phages. Neutrophils inﬁltration in and around hematomatakes place after 4 h, with the peak at day 2–3, remitting within
7 days after ICH. Neutrophils may disrupt neurons directly by
the ROS or indirectly, by proinﬂammatory proteases activa-
tion. Microglial cells monitor the well-being of their environ-
ment, being able to respond to signs of homeostatic
disturbance with a program of supportive and protective
activities, to safeguard innate defense mechanisms, or to
assist in speciﬁc immune reactions. There are many molecules
involved in the inﬂammatory reactions in the central nervous
system: TNF-a, the interferons (IFN), Il-1, -2, -3, -4, -6, -10, -12,
-15, -18, transforming growth factor b (TGF-b), colony-
stimulating factors (CSF), platelet-derived growth factor
(PDGF), epidermal growth factor (EGF), ﬁbroblast growth factor
(FGF), insulin-like growth factors (IGF), and neurotrophic
factors such as nerve growth factor (NGF), neurotrophins
(NT-3 and -4), or brain-derived neurotrophic factor (BDNF). The
principal sources of cytokines in the brain are activated
microglia/macrophages. Cytokines can be also released by
many cell types, including microglia, astrocytes, neurons and
endothelial cells. Nevertheless, evidence also supports the
involvement of peripherally derived cytokines in brain
inﬂammation. After ICH in humans, the blood–brain barrier
permeability increases. Therefore, peripherally derived mono-
nuclear phagocytes, T-lymphocytes, natural killer cells, and
polymorphonuclear neutrophilic leukocytes, which produce
and secrete cytokines, can all cross the BBB and contribute to
brain inﬂammation [16,17].
In ICH and ischemic stroke patients levels of inﬂammatory
cytokines change in the course of the disease. The serum level
of Il-6 was most markedly elevated in the patients with acute
stroke and tended to decrease thereafter. However, its level
remained signiﬁcantly elevated even at day 7. The level of TGF-
b was signiﬁcantly decreased at day 1 and day 3 and tended to
return toward the control value thereafter. Il-6 has both
proinﬂammatory and immunomodulatory actions. TGF-b
plays mainly an immunomodulatory role in pathological
conditions with a signiﬁcant antagonistic effect against
proinﬂammatory cytokine TNF-a [18]. Increased levels of Il-6
and Il-10 on the second day after ICH are associated with
consciousness disturbances severity [19].
ROS are generated as by-products of cellular metabolism
primarily in mitochondria, by neutrophils, endothelium and
activated microglia. They are produced while electrons are
leaking the respiratory chain and thus the amount of ROS
formed, has been reported to be proportional to partial
pressure of oxygen in the tissue. In addition to the mitochon-
drial electron transport chain, there are other ROS producing
mechanisms, e.g. system of cytochrome P-450, oxidative
enzymes, such as endothelial xanthine oxidase, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases, myelo-
peroxidases (MPO) of phagocytic cells, and arachidonate
oxygenases. ROS have cytotoxic effects leading to cell
destruction and degradation. They act both in ischemic and
hemorrhagic damage to the brain [20].
The aim of ICH treatment should be the decrease in
secondary ischemia, edema and intracranial pressure, as well
as providing oxygen supply and optimizing cerebral metabo-
lism. The treatment of ICH is still unsatisfactory, beside many
conducted trials. Thus, new mechanisms of existing drugs
should be considered and the use of new drugs should be tested.
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CoA) reductase inhibitors have pleiotropic properties acting on
elements of immune system [21]. They inhibit inﬂammation,
ROS development and clot forming. These drugs activate
endothelium, nitric oxide (NO) availability, promote angio-
genesis, neurogenesis and synaptogenesis. In the animal
model atorvastatin exhibited signiﬁcant increase in vascular
endothelial growth factor (VEGF), endogenous cell prolifera-
tion and increase in the level of synaptic protein (synapto-
physin). These data indicated that atorvastatin induced brain
plasticity and has neurorestorative activity [22].
In the animal model, simvastatin treatment was proved to
decrease tissue loss and hematoma volume after 4 weeks, but
there was no such an effect in relation to atorvastatin. The use
of those statins was associated with decreased neurological
deﬁcit and greater proliferation activity of neurons. More
evident and faster effect was observed in simvastatin group [4].
Atorvastatin promotes synaptogenesis and decreases severity
of neurological deﬁcit after ICH [23]. Differences between types
of statins may be connected with the fact, that simvastatin in a
higher extent crosses the BBB and has more evident
neuroprotective properties [24].
Another animal model study showed that atorvastatin has
no effect on reduction of hematoma volume, but there was
observed the reduction of hemispheric atrophy and decreased
expression of the inducible nitric oxide synthase (iNOS), MPO
and microglia. Atorvastatin increased endothelial nitric oxide
synthase (eNOS) expression and sensorimotor recovery after
experimental ICH in a dose-dependent manner [25]. Brain
damage is associated with apoptosis, which is stimulated by
apoptotic signaling molecules Fas ligand (FasL) and TNF,
microglia, iNOS and probably by thrombin [26]. Thus, inhibiting
iNOS by statins may be one of the factors preventing the brain
atrophy.
Statins inhibit cytokines inﬁltration after ICH, such as TNF-
a and IFN-g [25].
Guanosine triphosphate (GTP) binding proteins, such as Rho,
Rac and Ras undergo isoprenylation. This process affects
leukocytes ability to cross BBB and may be inhibited by statins
[27].
Statins inhibit ROS production by downregulation of
angiotensin-1 receptor gene expression and by inhibition of
GTPase Rac1 which is critically involved in the activation of
NADPH oxidase by preventing the geranylgeranyl-dependent
translocation of Rac1 from the cytosol to the cell membrane. In
addition, statins upregulate eNOS via inhibition of geranylger-
anylation of the small G-protein Rho. Antioxidative properties
are also associated with stimulation of catalase, supraoxide
dismutase (SOD), thioredoxin and heme oxidase-1 [28]. The
upregulation of eNOS and subsequent increased bioavailabili-
ty of NO is one of the most important pleiotropic effects of
statins. Several crucial functions such as vasodilation, as well
as antiinﬂammatory, proﬁbrinolytic, antiaggregant, antioxi-
dant, and antiapoptotic effects are tightly connected to the
endothelium and the release of NO. NO also has been shown to
promote neo-angiogenesis and to stimulate endothelial
progenitor cells in the bone marrow, supporting reendothe-
lialization and vascular remodeling after vascular damage [29].
The problem of statin discontinuation was highlighted for
the ﬁrst time in acute coronary syndrome and then in strokepatients [21]. There is pathological evidence of possible
harmful rebound reaction after withdrawal of statins in stroke
patients. Chronic intake of statins blocks isoprenoid-depen-
dent Rho membrane translocation and GTP-binding activity
and thus leads to accumulation of non-isoprenylated Rho
protein in the cytosol. Withdrawal of atorvastatin restores the
availability of isoprenoids, results in a massive membrane
translocation and activation of Rho, causing downregulation
of endothelial NO production. Two days after the withdrawal
of statin treatment, endothelial NO production decreases up to
90% [30].
Discontinuation of statins after onset of symptoms
completely abrogates its beneﬁcial effect and this could be
due to the rebound effect on NO [31]. In ICH patients there was
revealed relationship between in-hospital statin discontinua-
tion and stroke severity and 30-day mortality [32].
Previous studies indicate possible beneﬁcial effect of statin
use in acute phase in animal models. The prospective studies
of the statin use in the acute phase of ICH in humans has not
been provided yet. There has only been one retrospective
analysis made [40]. Studies regarding the preadmission statin
use and ICH outcome are listed in Table 1.
3. Subarachnoid hemorrhage
Subarachnoid hemorrhage is connected with mortality as high
as 46% and severe psychomotor disability, with incidence of 2–
32/100,000. After aneurysmal SAH, angiographic vasospasm is
seen in 30–70% of patients, with a typical onset from 3 to 5 days
after the hemorrhage, maximal narrowing at 5–14 days, and a
gradual resolution over 2–4 weeks [41,42].
Prominent complication of SAH is delayed ischemic neuro-
logical deﬁcit (DIND) or delayed cerebral ischemia (DCI), which is
a major cause of disability and mortality, with prevalence of 33–
38%. It can lead to focal neurological deﬁcit or death. Symptoms
can be reversible or progress into complete stroke conﬁrmed by
neuroimaging tests in 10–13% cases. DIND is associated with
worse prognosis, its severity correlates with the volume of
extravasated blood. The explanation may be vasospasm or
spreading of cortical depolarization [43]. Another hypothesis of
DIND is the early cerebral autoregulatory failure [44].
It is believed that the most important role in the pathogene-
sis of vasospasm plays the depletion of NO, which is a potent
vasodilator. Other theories postulate that the presence of
extravasated hemoglobin and its degradation products may
disrupt signaling between the vascular endothelium and the
underlying smooth muscular layer. This latter process induces a
cascade of metabolic events, which ﬁnally leads to endothelin-1
(ET-1) production and cerebral vasoconstriction. ET-1 is a potent
vasoconstrictor and is produced when ischemia occurs. Its
increased level in the plasma and CSF (cerebrospinal ﬂuid)
correlates with the persistence of cerebral vasospasm. Another
mechanism proposed to be implicated in the development of
cerebral vasospasm is the free radical oxidation of bilirubin to
bilirubin oxidation products and inﬂammatory state due to
leukocyte recruitment.
Adhesion molecules, such as ICAM-1 (intercellular adhe-
sion molecule-1), VCAM-1 (vascular cell adhesion molecule-1)
and E-selectin, have been found to be elevated in the CSF.
Table 1 – Studies regarding the association between statin use and ICH.
Study Number of
ICH patients
The association that was evaluated The effect of statin use
Dowlatshahi et al. [32] 2466 Preadmission statin use with outcomes
(severity of stroke at presentation, mRS at
discharge, 30-day mortality, and 6-month
mortality)
No association
Fitzmaurice et al. [10] 629 Preadmission statin use with 90-day
outcomes and mortality
No association
Fitzmaurice et al. [10] 79 Post-ICH statin use with the risk of
recurrence
No association
King et al. [33] 1381 Preadmission statin use with 30-day
mortality
No association
Bifﬁ et al. [34] 2521 Preadmission statin use with 90-day
functional outcome and mortality
Favorable outcome and reduced
mortality
Leker et al. [35] 312 Preadmission statin use with stroke
severity and outcomes
Lower baseline NIHSS, less
systemie complications; reduced
mortality and neurological
disability
Naval et al. [36] 314 Preadmission statin use with 30-day
mortality and outcomes at discharge
No association between
functional outcome; decreased
mortality
Naval et al. [37] 125 Preadmission statin use with volume of
perihematomal edema on initial head CT
Reduced volume of
perihematomal edema
Ricard et al. [38] 303 Preadmission statin use with ICH volume
variation of ﬁrst follow up CT scans and
death
Increased baseline ICH volume,
increased progression of ICH
volume; no association with
mortality
Woo et al. [39] 1578 Preadmission statin use with risk of ICH in
association with Apolipoprotein E (ApoE)
polymorphisms
Higher risk for lobar ICH in ApoE4/
E4 and ApoE2/E4 genotypes
Niewada et al. [40] 3111 Preadmission and in-hospital statin use
with outcomes and mortality
Preadmission use: higher in-
hospital mortality; in-hospital
use: lower in-hospital mortality
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Several cytokines have been found to be upregulated in
cerebral vasospasm, including TNF-a, Il-1, Il-6, and Il-8 [45].
Statins can prompt a beneﬁcial activity in SAH, because
they inhibit transvascular migration and proliferation of
leukocytes, activity of ICAM-1, VCAM-1, Il-1b, Il-6, Il-8 and
TNF-a. The antioxidative effect is also of clinical importance
[21,46,47].
The deﬁnition of DCI had not been unambiguous, because
the pathomechanism of vasoconstriction in SAH is not clear. A
multidisciplinary research group proposed the deﬁnition of
DCI as follows: a clinical deterioration caused by DCI is the
development of focal neurological signs, such as aphasia or
hemiparesis, and a decrease of 2 points in the level of
consciousness in the Glasgow Coma Score. This should last for
at least 1 h, should not be apparent immediately after
aneurysm occlusion, and cannot be attributed to other causes
by means of clinical assessment, CT (computed tomography)
or MRI (magnetic resonance imaging) scanning of the brain,
and appropriate laboratory studies. The use of the word
‘‘vasospasm’’ should be restricted to descriptions of a
radiological test and not applied to clinical manifestations
of DCI [48].
Statins inhibit NADPH oxidase, superoxide production and
upregulate the expression and activity of eNOS, which
improves endothelial reactivity and cerebral blood ﬂow [28].Other effects of statins possibly beneﬁcial in SAH were cited
above [22].
In a case study it was suggested that there was an inverse
relationship between the use of statins and risk of cerebral
aneurysm rupture [49].
On the other hand statin users have a higher risk for
subarachnoid hemorrhage-related vasospasm, but authors
suggested that the underlying cause of this observation could
be the abrupt statin withdrawal [50].
Acute pravastatin treatment after SAH reduces traditional
rescue therapy for vasospasm after aneurysmal subarachnoid
hemorrhage, improves cerebral autoregulation and reduces
DIND [51]. Improvement in early outcome has proved robust at
6 months, particularly in relation to physical and psychosocial
outcome [52].
A meta-analysis including 158 patients showed that statin
therapy after aneurysmal SAH signiﬁcantly reduces the
incidence of vasospasm (relative risk [RR] = 0.73; 95% CI,
0.54–0.99), DIND (RR = 0.38; 95% CI, 0.17–0.83) and mortality
(RR = 0.22; 95% CI, 0.06–0.82) [53].
In contradiction to these results, a meta-analysis including
four, only randomized trials, showed no effect of pravastatin
and simvastatin in SAH patients, but the total number of
subjects was only 190 and two of analyzed studies were
identical to the prior paper [53,54]. A new randomized study
with 38 SAH patients showed no beneﬁcial effect of simva-
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mortality or improved functional outcome [55]. More
information about statin treatment will be given after
completing the STASH (Simvastatin in Aneurysmal Sub-
arachnoid Hemorrhage) study with the use of simvastatin in
1600 patients. Initial results of that study demonstrate
potential beneﬁts [56].
There is no exact time when statin treatment should be
introduced, but in cited studies it took place within ﬁrst 96 h
after SAH. Vasospasm initiates since forth day after the onset,
so the time of ﬁrst 96 h seems to be reasonable.
4. Conclusions
Taking into consideration the serious outcomes, mortality,
psychomotor and verbal deﬁcits in both ICH and SAH patients,
searching for new therapeutic options is desirable. The
unquestionable role of inﬂammatory factors in the patho-
genesis of these disorders justiﬁes considering statin treat-
ment. Previous results are contradictory, but questions
concerning beneﬁcial effects are probably due to small
samples count.
More studies on greater groups are indispensable with
taking into account physicochemical properties and dose of
particular statins, that can affect the ability of central nervous
system penetration [57].
The important issue is the dosing of statins. High-dose
versus usual-dose statin therapy in coronary artery disease
is beneﬁcial for high-risk patients [58]. There are several
studies that conﬁrmed dose-depending effects of statins,
even in all ischemic stroke subtypes, but it is not fully
known presently if higher doses of statins should be used in
ischemic stroke patients [59,60]. The disparate ﬁndings of
the Medical Research Council/British Heart Foundation
Heart Protection Study (HPS) and the Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) trials
suggest that careful selection of patients with atheroscle-
rotic stroke is critical for realizing a beneﬁt to statin
treatment [61].
In ICH patients the effect of statins did not alter results after
adjustment for statin dose [34,42] or such an information was
not presented [35,36].
There are limited data available regarding the statin dosing
in SAH patients. A potentially beneﬁcial effect was observed
after the use of pravastatin at dose of 40 and 80 mg [51,52]. The
beneﬁcial or no effect was observed with the use of
simvastatin 80 mg [53–55]. The potential role of dose and type
of statins needs explanation and more attention to be paid in
the future studies.
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